BioSig Technologies, Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
BioSig Technologies (Nasdaq: BSGM) will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 3 PM ET. CEO Ken Londoner will share insights about the company’s PURE EP™ System, which enhances signal fidelity in electrophysiology. This system has been utilized by over 40 physicians in more than 600 patient cases across eight clinical sites. Interested parties can schedule one-on-one meetings and view the live webcast via the provided links.
- None.
- None.
Westport, CT, April 05, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Ken Londoner, CEO of BioSig Technologies, will provide a corporate overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12th, 2021 at 3 PM ET.
BioSig’s PURE EP™ System is an advanced signal acquisition and processing platform that seeks to set a new standard in electrophysiology. The system provides essential diagnostic signals with high clinical value in all types of cardiac ablations. More than 40 physicians have completed over 600 patient cases with the PURE EP™ System across 8 clinical sites.
For parties interested in scheduling a one-on-one meeting with BioSig management, please contact the conference coordinators at conferences@needhamco.com.
To view the live webcast of the event, please click here.
A replay of the presentation will be available on the webcast page for 90 days and on the BioSig website.
Date and Time: April 12th, 2021 at 3 PM ET
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is the purpose of BioSig Technologies' presentation at the Needham Conference?
When is the BioSig presentation scheduled at the Needham Conference?
How many physicians have used the PURE EP™ System?
Where can I watch the BioSig Technologies conference presentation?
What does the PURE EP™ System do?
